Hockey Legend Mario Lemieux Helps Fund New Childhood Lymphoma Center

Back in the fall of 1992, Pittsburgh Penguins star Mario Lemieux was blowing away the rest of the National Hockey League with some of the most amazing statistics ever recorded in pro hockey. Through the first 40 games, the 6'6" superstar had scored 39 goals and 65 assists for 104 points. Nobody else was even close.

But then in early January of 1993 came the shock of a lifetime: Mario was diagnosed with early-stage Hodgkin's lymphoma.

Treatment began almost immediately. For Mario, this meant radiotherapy only (no chemotherapy). For just under two months Mario received radiation treatments.

He underwent his final treatment on the afternoon of 2 March 1993, and was in Philadelphia that night to play his first game back. Despite the bitter rivalry between Pittsburgh and Philadelphia, Mario received an ovation from the Philly faithful. In the game, he registered a goal and an assist. That's one of the all-time great sports stories, according to NHL Commissioner Gary Bettman.

From there, he wouldn't skip a beat, scoring a miraculous 30 goals and 26 assists during the final 20 games of the season. Thus in just 60 games that year, Mario scored 69 goals and 91 assists for 160 points in just 60 games. Playing in one quarter fewer games than virtually everyone else, he still won the league scoring title, easily beating out Buffalo's Pat Lafontaine, who tallied 148 points in 84 games.

Mario and Rare Lymphomas

These days Lemieux is a Hall-of-Famer and co-owner of those same Pittsburgh Penguins, but he is also the head of the Mario Lemieux Foundation, which he founded during that very remarkable year for him, 1993.

Yesterday it was announced that the Foundation would be partnering with the University of Pittsburgh Medical Center (UPMC) to create the $5 million Mario Lemieux Lymphoma Center for Children and Young Adults, to be housed at Children's Hospital of UPMC in Lawrenceville.

"The support of the Lemieux Foundation gives us the ability to enhance our basic and clinical research in a way that could lead to improved and potentially new treatments for patients around the world who currently have very limited options," said Linda McAllister-Lucas, chief of the Division of Pediatric Hematology/Oncology who will lead the new center.

"I was fortunate to have a type of lymphoma that has proven treatments with good outcomes," added Mario. "I want to create a place of hope for kids and young adults and their families who are diagnosed with lymphomas that have no known cures."

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap